Dr. Richard Morris is Chief Executive Officer of PharmaSeq. Dr. Richard Morris has over 25 years experience in the areas of biomedical instrumentation and biotechnology. Shortly after receiving his Ph.D. in biochemistry from the University of California, he began his career at Durrum Instruments (now Dionex Corp., Sunnyvale, CA). After many years of increasing responsibility at Dionex, Dr. Morris was promoted to Vice President of International Operations and was responsible for operations in Europe, Japan and China. He then became Vice President of Worldwide Sales at Molecular Dynamics (Sunnyvale, CA), where he was responsible for sales and service operations management, including subsidiaries in North America, Europe and the Pacific Rim. He then joined Sigma-Aldrich Corp. (St. Louis, MO) as President of Sigma-Aldrich Research. During his four years at this $800 million revenue division, he directed worldwide sales of catalog research products, and the organization and supervision of sales forces, marketing and associated services. In addition, he integrated multiple brands into the Research Division, created a national account strategy, instituted product management approval, and opened new markets for the company. Dr. Morris’ most recent position was at CambridgeSoft Corp. (Cambridge, MA), a company specializing in desktop software solutions for chemical compound modeling, where he was President of e-Commerce and Chief Marketing Officer.
Board of Directors
Dr. Wlodek Mandecki, Chairman
(resume provided at the top of this web page)
Zbigniew Darzynkiewicz, M.D., Ph.D.
Zbigniew Darzynkiewicz, M.D., Ph.D., is the Director of the Brander Cancer Research Institute at the New York Medical College and the Professor of Medicine and Pathology at the same College. Formerly, Dr. Darzynkiewicz was the Professor of Cell Biology and Genetics at Cornell University Medical School, a Member of the Sloan-Kettering Institute for Cancer Research, the Head of the Experimental Cell Research Laboratory, and the Director of the Flow Cytometry Core Facility Network, all at the Sloan-Kettering Institute, New York. Dr. Darzynkiewicz is the Editor of the Experimental Cell Research and Cell Proliferation and a Member of the Editorial Boards of nine other scientific journals. He is the past President of The Cell Kinetics Society and also past President of the International Society for Analytical Cytology (ISAC; with over 2,000 members from over 60 countries). Dr. Darzynkiewicz has authored 400 original publications and over 75 chapters and reviews in books devoted to the subject of cell growth, regulation of the cell cycle and apoptosis, and has authored and/or edited 11 books. He holds five US patents, several are pending. His publications have been cited over 9,000 times in the scientific literature. He consults several pharmaceutical companies and is on the Board of Scientific Advisors of the Alfacell Company (Bloomfield, NJ). Dr. Darzynkiewicz received his M.D. (with highest honors) in 1960 and his Ph.D. in 1966 from the Medical School of Warsaw, Warsaw, Poland. He completed his post-graduate studies at the State University of New York at Buffalo and the Medical Nobel Institute of Karolinska Institute, Stockholm, Sweden. Since 1974, he has been associated with the Sloan-Kettering Institute for Cancer Research, and since 1990, he has been with New York Medical College, Valhalla, New York.
Mr. David Freedman
Mr. David Freedman is the founder and current CEO of New Brunswick Scientific Corporation (NBS) in Edison, NJ. NBS is a manufacturer of instrumentation for medical laboratories and employs approximately 400 people. Annual sales are over $50 million per annum. NBS is publicly traded on the NASDAQ.
Mr. David Freedman has over 50 years of experience in managing a biomedical instrumentation company. He founded NBS in 1946. NBS's products, such as rotary shakers, fermentors and variety of incubators, quickly became standards in the fields of biochemistry and biotechnology. Mr. Freedman holds about 200 patents and has authored many scientific publications. Mr. Freedman founded six companies other than NBS, including Princeton AquaScience, Bioinstrument Company, Segnatron and others. He was a member of the Board of Directors of six companies. Currently, Mr. Freedman is Chairman of the Board and CEO of NBS.
Dr. Richard G. Morris
(resume provided at the top of this web page)
Scientific Advisors
